Table 2.
Baseline characteristics of the cohort. Data are shown as median (interquartile range) for continuous variables and percentage (n) for discrete variables.
| All (12,381) | Men (6,349) | Women (6,032) | |
|---|---|---|---|
| Sex (women) | 48.7% (6032) | 0% | 100.0% |
| Age [y] | 54.0 (45.0/64.0) | 55.0 (46.0/64.0) | 54.0 (45.0/63.0) |
| BMI [kg/ m2] | 26.4 (23.8/29.7) | 27.1 (24.8/30.0) | 25.5 (22.8/29.3) |
| Obesity (n) | 23.5% (2905) | 24.8% (1573) | 22.1% (1332) |
| Diabetes (n) | 7.3% (900) | 9.3% (589) | 5.2% (311) |
| Hypertension (n) | 49.3% (6104) | 54.5% (3457) | 43.9% (2647) |
| Dyslipidemia (n) | 26.6% (3274) | 36.4% (2285) | 16.4% (989) |
| Kidney function | |||
| Creatinine [mg/dl] | 0.79 (0.71/0.89) | 0.87 (0.80/0.96) | 0.72 (0.67/0.78) |
| eGFR [ml/min/1.73 m2] | 94.9 (86.5/102.9) | 95.6 (87.6/103.7) | 94.0 (85.5/102.0) |
| Albuminuria (n) | 6.0% (732) | 7.4% (461) | 4.6% (271) |
| Biomarkers | |||
| Cholesterol [mg/dl] | 219 (193/246) | 215 (189/240) | 223 (197/251) |
| Triglycerides [mg/dl] | 103 (77/145) | 115 (85/161) | 94 (71/126) |
| LDL-cholesterol [mg/dl] | 137 (115/161) | 137 (116/160) | 137 (114/161) |
| HDL-cholesterol [mg/dl] | 55.6 (46.0/67.0) | 49.0 (42.0/57.0) | 64.0 (54.0/74.6) |
| HbA1c [%] | 5.5 (5.2/5.8) | 5.5 (5.2/5.8) | 5.5 (5.2/5.8) |
| CRP [mg/l] | 1.5 (0.5/3.0) | 1.4 (0.5/2.7) | 1.6 (0.5/3.3) |
| Uric acid [mg/dl] | 4.60 (3.70/5.70) | 5.40 (4.70/6.30) | 3.80 (3.14/4.60) |
| Urea nitrogen [mg/dl] | 14.0 (11.0/16.0) | 15.0 (12.0/17.0) | 13.0 (11.0/15.0) |
| Albumin [g/l] | 42.0 (40.0/44.0) | 42.0 (40.0/44.0) | 41.0 (39.0/44.0) |
| ALAT [U/l] | 31 (25/41) | 37 (29/47) | 27 (22/33) |
| GGT [U/l] | 24 (17/37) | 30 (22/46) | 19 (14/27) |
| Alkaline phosphatase [U/l] | 64 (54/77) | 64 (55/76) | 64 (53/78) |
| Bilirubin [mg/dl] | 0.64 (0.49/0.85) | 0.71 (0.55/0.93) | 0.57 (0.44/0.74) |
| White cell count [1/nl] | 6.83 (5.79/8.15) | 6.78 (5.70/8.07) | 6.90 (5.87/8.20) |
| Red cell count [1/pl] | 4.70 (4.44/4.98) | 4.90 (4.66/5.14) | 4.51 (4.30/4.73) |
| Haemoglobin [g/dl] | 14.3 (13.5/15.2) | 15.0 (14.4/15.7) | 13.6 (13.0/14.2) |
| Homocystein [µmol/l] | 11.0 (9.3/13.2) | 12.0 (10.2/14.2) | 10.1 (8.5/12.0) |
| Cardiovascular function | |||
| Systolic blood pressure [mmHg] | 129 (119/141) | 132 (122/142) | 126 (115/138) |
| Diastolic blood pressure [mmHg] | 82.0 (76.0/88.5) | 83.5 (78.0/89.5) | 80.5 (74.5/87.0) |
| Ejection fraction [%] | 63.5 (60.0/67.1) | 63.0 (59.5/66.7) | 64.2 (60.7/67.5) |
| E/E'-Ratio | 7.08 (5.85/8.78) | 6.89 (5.66/8.56) | 7.29 (6.07/9.01) |
| Flow mediated dilatation [%] | 7.34 (4.58/10.89) | 6.11 (3.78/8.77) | 9.20 (5.88/13.32) |
| Augmentation index [%] | 13.90 (2.62/28.29) | 8.18 (-1.74/20.26) | 20.55 (9.16/35.64) |
| Medications | |||
| Antidiabetics (n) | 5.0% (618) | 6.7% (420) | 3.3% (198) |
| Diuretics (n) | 4.1% (504) | 4.0% (250) | 4.2% (254) |
| Beta-Blockers (n) | 15.7% (1919) | 16.2% (1013) | 15.1% (906) |
| Calcium antagonists (n) | 6.4% (789) | 7.5% (472) | 5.3% (317) |
| Agents acting on RAS (n) | 22.1% (2701) | 25.7% (1610) | 18.2% (1091) |
| Other antihypertensives (n) | 0.8% (68) | 0.8% (34) | 0.8% (34) |
| Lipid modifying agents (n) | 12.4% (1522) | 15.0% (938) | 9.8% (584) |